Alzheimer's disease is the world's most common neurodegenerative disease, affecting more than 50 million people globally. Alzheimer's disease is also among the most fatal, landing as one of the top ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...

Clinical trials in Alzheimer disease (AD) generally allow participants to continue receiving concomitant medications, including cholinesterase inhibitors (ChEIs) and memantine, if the dose is stable.

Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...